Medicare Rolls Out Alzheimer Patient Registry After FDA Approval

The Medicare agency officially launched its patient registry for the Alzheimer’s drug Leqembi on Thursday just minutes after the FDA granted traditional approval for the infusion therapy.

The Center for Medicare & Medicaid Services will now cover Eisai Co. and Biogen Inc.’s Leqembi for patients with a prescriber or clinical team participating in a patient registry, widening coverage for the drug that costs $26,500 for annual treatment. The agency had promised to expand coverage immediately after the Food and Drug Administration converted Leqembi’s approval from accelerated to traditional. The CMS previously only covered the drug for patients in clinical ...